Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The prospective and open phase II clinical trial of whole brain radiotherapy combined with anti-angiogenesis therapy for wild-type EGFR non-squamous NSCLC with multiple brain metastases

Next Previous
Search
Trial Profile

The prospective and open phase II clinical trial of whole brain radiotherapy combined with anti-angiogenesis therapy for wild-type EGFR non-squamous NSCLC with multiple brain metastases

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 15 Mar 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top